Prevalence of invasive lung cancer in pure ground glass nodules less than 30 mm: A systematic review

IF 7.6 1区 医学 Q1 ONCOLOGY
Abdullah AlShammari , Akshay Patel , Mark Boyle , Chiara Proli , Jose Alvarez Gallesio , Anuj Wali , Paulo De Sousa , Eric Lim
{"title":"Prevalence of invasive lung cancer in pure ground glass nodules less than 30 mm: A systematic review","authors":"Abdullah AlShammari ,&nbsp;Akshay Patel ,&nbsp;Mark Boyle ,&nbsp;Chiara Proli ,&nbsp;Jose Alvarez Gallesio ,&nbsp;Anuj Wali ,&nbsp;Paulo De Sousa ,&nbsp;Eric Lim","doi":"10.1016/j.ejca.2024.115116","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The IASLC TNM proposal suggests that pure ground glass nodules less than 30 mm should be classified as cTis corresponding to pathologic adenocarcinoma in situ implying no invasive malignancy potential. We sought to ascertain the proportion of pure ground glass nodules that harbour tissue confirmed minimally invasive or invasive adenocarcinoma.</div></div><div><h3>Methods</h3><div>We analyzed data from 3874 individuals with pure ground glass nodules less than 30 mm, reported in 28 observational studies identified through a systematic search of electronic databases. The primary outcome was the prevalence of invasive malignancy by random effects meta-analysis, and we used meta-regression to determine the impact of baseline risk, size, and country of investigation on overall effect size. The study was registered with PROSPERO (CRD42021286261).</div></div><div><h3>Results</h3><div>All published studies were retrospective (n = 28) and the majority conducted in Asia (n = 25). Baseline patient cohorts were mainly from published surgical series (n = 22) or lung cancer screening programs (n = 6). The proportion of minimally invasive and invasive cancer ranged from 0.9 % to 100 % with a pooled prevalence of 42.4 % [95 % CI: 0.28, 0.57].</div><div>Considerable heterogeneity was observed (I<sub>2</sub> =99 %) and patient selection was the most significant contribution, accounting for 73 % of the observed heterogeneity (p &lt; 0.0001). Meta-regression based on size selection and country of investigation revealed no significant contribution to effect size effect or heterogeneity.</div></div><div><h3>Conclusions</h3><div>Pure ground glass nodules less than 30 mm harbour a high proportion of invasive malignancy, contrary to the IASLC staging proposals and opinions from numerous guidelines across the world.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115116"},"PeriodicalIF":7.6000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924017234","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The IASLC TNM proposal suggests that pure ground glass nodules less than 30 mm should be classified as cTis corresponding to pathologic adenocarcinoma in situ implying no invasive malignancy potential. We sought to ascertain the proportion of pure ground glass nodules that harbour tissue confirmed minimally invasive or invasive adenocarcinoma.

Methods

We analyzed data from 3874 individuals with pure ground glass nodules less than 30 mm, reported in 28 observational studies identified through a systematic search of electronic databases. The primary outcome was the prevalence of invasive malignancy by random effects meta-analysis, and we used meta-regression to determine the impact of baseline risk, size, and country of investigation on overall effect size. The study was registered with PROSPERO (CRD42021286261).

Results

All published studies were retrospective (n = 28) and the majority conducted in Asia (n = 25). Baseline patient cohorts were mainly from published surgical series (n = 22) or lung cancer screening programs (n = 6). The proportion of minimally invasive and invasive cancer ranged from 0.9 % to 100 % with a pooled prevalence of 42.4 % [95 % CI: 0.28, 0.57].
Considerable heterogeneity was observed (I2 =99 %) and patient selection was the most significant contribution, accounting for 73 % of the observed heterogeneity (p < 0.0001). Meta-regression based on size selection and country of investigation revealed no significant contribution to effect size effect or heterogeneity.

Conclusions

Pure ground glass nodules less than 30 mm harbour a high proportion of invasive malignancy, contrary to the IASLC staging proposals and opinions from numerous guidelines across the world.
小于 30 毫米的纯磨碎玻璃结节中浸润性肺癌的发病率:系统综述。
背景:IASLC TNM 建议将小于 30 毫米的纯磨玻璃结节归类为 cTis,与病理原位腺癌相对应,这意味着没有侵袭性恶性肿瘤的可能性。我们试图确定纯磨碎玻璃结节中藏有组织证实的微侵袭性或侵袭性腺癌的比例:我们分析了通过系统搜索电子数据库发现的 28 项观察性研究中报告的 3874 例纯磨玻璃结节患者的数据,这些结节小于 30 毫米。主要结果是通过随机效应荟萃分析得出的侵袭性恶性肿瘤发病率,我们使用荟萃回归法确定了基线风险、大小和调查国家对总体效应大小的影响。该研究已在 PROSPERO(CRD42021286261)注册:所有已发表的研究均为回顾性研究(28 项),大部分研究在亚洲进行(25 项)。基线患者队列主要来自已发表的手术系列(22 人)或肺癌筛查项目(6 人)。微创和浸润性癌症的比例从0.9%到100%不等,总患病率为42.4% [95 % CI: 0.28, 0.57]。观察到了相当大的异质性(I2 = 99 %),而患者选择是最重要的原因,占观察到的异质性的 73 %(P 结论:患者选择是最重要的原因,占观察到的异质性的 73 %):小于 30 毫米的纯磨碎玻璃结节具有很高比例的浸润性恶性肿瘤,这与 IASLC 分期建议和全球众多指南的意见相悖。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Journal of Cancer
European Journal of Cancer 医学-肿瘤学
CiteScore
11.50
自引率
4.80%
发文量
953
审稿时长
23 days
期刊介绍: The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信